Type I interferon: understanding its role in HIV pathogenesis and therapy (Q38348388)

2 September 2017

1 reference

title

Type I interferon: understanding its role in HIV pathogenesis and therapy (English)

1 reference

2 September 2017

Netanya S Utay

2

0 references

Steven E Bosinger

series ordinal

1

object named as

Steven E Bosinger

1 reference

2 September 2017

publication date

1 March 2015

1 reference

2 September 2017

published in

Current HIV/AIDS reports

1 reference

2 September 2017

volume

12

1 reference

2 September 2017

issue

1

1 reference

2 September 2017

page(s)

41-53

1 reference

https://scigraph.springernature.com/pub.10.1007/s11904-014-0244-6

2 September 2017

exact match

0 references

cites work

Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study).

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-alpha immunization: a 30-month follow-up report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Microbial translocation in HIV infection: causes, consequences and treatment opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Pathogenic simian immunodeficiency virus infection is associated with expansion of the enteric virome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Plasmacytoid dendritic cells in HIV infection: striking a delicate balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Evidence of dysregulation of dendritic cells in primary HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-α-producing and partially matured phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

In acute pathogenic SIV infection plasmacytoid dendritic cells are depleted from blood and lymph nodes despite mobilization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

SIV infection induces accumulation of plasmacytoid dendritic cells in the gut mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Multi-functional plasmacytoid dendritic cells redistribute to gut tissues during simian immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Longitudinal analysis of distribution and function of plasmacytoid dendritic cells in peripheral blood and gut mucosa of HIV infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Plasmacytoid dendritic cells are recruited to the colorectum and contribute to immune activation during pathogenic SIV infection in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Plasmacytoid dendritic cell dynamics tune interferon-alfa production in SIV-infected cynomolgus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Blocking TLR7- and TLR9-mediated IFN-α production by plasmacytoid dendritic cells does not diminish immune activation in early SIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Plasmacytoid dendritic cells contribute to systemic but not local antiviral responses to HSV infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Downregulation of robust acute type I interferon responses distinguishes nonpathogenic simian immunodeficiency virus (SIV) infection of natural hosts from pathogenic SIV infection of rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Plasmacytoid dendritic cells suppress HIV-1 replication but contribute to HIV-1 induced immunopathogenesis in humanized mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Intact type I Interferon production and IRF7 function in sooty mangabeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Tetherin inhibits HIV-1 release by directly tethering virions to cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

SAMHD1 restricts HIV-1 replication and regulates interferon production in mouse myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

MX2 is an interferon-induced inhibitor of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Evolutionary analysis identifies an MX2 haplotype associated with natural resistance to HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Expression profile of host restriction factors in HIV-1 elite controllers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

The interferon-induced gene ISG15 blocks retrovirus release from cells late in the budding process

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

A diverse range of gene products are effectors of the type I interferon antiviral response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

A FOXO3-IRF7 gene regulatory circuit limits inflammatory sequelae of antiviral responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

IRF-7 is the master regulator of type-I interferon-dependent immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Polymorphisms in interferon regulatory factor 7 reduce interferon-α responses of plasmacytoid dendritic cells to HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

TRIM5 is an innate immune sensor for the retrovirus capsid lattice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

IFI16 is an innate immune sensor for intracellular DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Interferon γ-inducible protein (IFI) 16 transcriptionally regulates type i interferons and other interferon-stimulated genes and controls the interferon response to both DNA and RNA viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Innate DNA sensing is impaired in HIV patients and IFI16 expression correlates with chronic immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

The depletion of NK cells prevents T cell exhaustion to efficiently control disseminating virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Type I interferon regulation of natural killer cell function in primary and secondary infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Therapeutic depletion of natural killer cells controls persistent infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Type I interferon protects antiviral CD8+ T cells from NK cell cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Restoring function in exhausted CD8 T cells during chronic viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Blockade of chronic type I interferon signaling to control persistent LCMV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Molecular and transcriptional basis of CD4⁺ T cell dysfunction during chronic infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Persistent LCMV infection is controlled by blockade of type I interferon signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Enhancing SIV-specific immunity in vivo by PD-1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Interferon-alpha administration enhances CD8+ T cell activation in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Lack of efficacy of low dose oral interferon alfa in symptomatic HIV-1 infection: a randomised, double blind, placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Combined zidovudine and interferon-alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Combined treatment with zidovudine and lymphoblast interferon-alpha in patients with HIV-related Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Zidovudine-interferon-alpha combination therapy in patients with advanced human immunodeficiency virus type 1 infection: biphasic response of p24 antigen and quantitative polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

A randomized trial of interferon alpha therapy for HIV type 1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Virologic and immunologic activity of PegIntron in HIV disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Interferon-alpha produces significant decreases in HIV load

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Hepatitis C therapy with interferon-α and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/hepatitis C virus-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Innate immune responses and rapid control of inflammation in African green monkeys treated or not with interferon-alpha during primary SIVagm infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Treatment of SIV-infected sooty mangabeys with a type-I IFN agonist results in decreased virus replication without inducing hyperimmune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Transient increase of interferon-stimulated genes and no clinical benefit by chloroquine treatment during acute simian immunodeficiency virus infection of macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Reduction of immune activation with chloroquine therapy during chronic HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Glycerol monolaurate prevents mucosal SIV transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Zidovudine and interferon-alpha combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0244-6

Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response

21 January 2018

1 reference

12 December 2020

Efficacy of Kemron (low dose oral natural human interferon alpha) in the management of HIV-1 infection and acquired immune deficiency syndrome (AIDS).

1 reference

12 December 2020

Low-dose zidovudine in combination with either acyclovir or lymphoblastoid interferon-alpha in asymptomatic HIV-infected patients: a pilot study

1 reference

12 December 2020

Long-term treatment with recombinant interferon alpha-2b prolongs survival of asymptomatic HIV-infected individuals

1 reference

12 December 2020

Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection

1 reference

12 December 2020

Plasmacytoid dendritic cells in HIV infection

1 reference

12 December 2020

Anti-alpha interferon immunization: safety and immunogenicity in asymptomatic HIV positive patients at high risk of disease progression

1 reference

12 December 2020

Outcome of intervention with or without low dose oral interferon alpha in thirty-two HIV-1 seropositive patients in a referral hospital

1 reference

12 December 2020

Pegylated interferon-alpha 2a treatment of chronic SIV-infected macaques

1 reference

12 December 2020

Is presence of interferon predictive for AIDS?

1 reference

12 December 2020

A multicenter, randomized, controlled trial of three preparations of low-dose oral alpha-interferon in HIV-infected patients with CD4+ counts between 50 and 350 cells/mm(3). Division of AIDS Treatment Research Initiative (DATRI) 022 Study Group

1 reference

12 December 2020

An interim report on the effect of natural human interferon alpha (IFN-alpha) lozenges in patients seropositive for the human immunodeficiency virus type 1 (HIV-1).

1 reference

12 December 2020

Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: AIDS Clincal Trial Group 068

1 reference

12 December 2020

Three open-label studies of oral interferon alpha in the treatment of HIV disease

1 reference

12 December 2020

Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys

1 reference

12 December 2020

Acid-labile human leukocyte interferon in homosexual men with Kaposi's sarcoma and lymphadenopathy

1 reference

12 December 2020

Natural killer cells act as rheostats modulating antiviral T cells

1 reference

12 December 2020

Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial

1 reference

12 December 2020

IL-15 cis presentation is required for optimal NK cell activation in lipopolysaccharide-mediated inflammatory conditions

1 reference

12 December 2020

The effect of recombinant human interferon α BD compared to interferon α 2b on SIV infection in rhesus macaques

1 reference

12 December 2020

Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma

1 reference

12 December 2020

Recombinant leukocyte A interferon in Kaposi's sarcoma

1 reference

12 December 2020

Modulation of type I interferon-associated viral sensing during acute simian immunodeficiency virus infection in African green monkeys

1 reference

12 December 2020

Low dose oral interferon alpha 2a in HIV-1 seropositive patients: a double-blind, placebo-controlled trial

1 reference

12 December 2020

Combined zidovudine and interferon-alpha treatment in patients with AIDS-associated Kaposi's sarcoma

1 reference

12 December 2020

10.1007/S11904-014-0244-6

Identifiers

DOI

1 reference

2 September 2017

1 reference